Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.

Na RenShanshan LvXiang LiChong ShaoZiyuan WangYazhao MeiWendi YangWenzhen FuYunqiu HuLing ShaWeiwei HuZhenlin ZhangChun Wang

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)

This study deepened the understanding of the clinical characteristics, treatment, and follow-up of OPPG and LRP5-HBM; expanded the pathogenic gene spectrum of OPPG; and confirmed that bisphosphonates were effective for OPPG. Additionally, it was found that Ala242Thr mutation could not protect LRP5-HBM patients from age-related bone loss. This phenomenon deserves further study.

Keyphrases

bone loss
end stage renal disease
bone mineral density
chronic kidney disease
ejection fraction
transcription factor
prognostic factors
peritoneal dialysis
gene expression
combination therapy
soft tissue
genome wide
postmenopausal women
low density lipoprotein
patient reported
genome wide analysis